Search results for "RIP"

showing 10 items of 9780 documents

Role of ATP during the initiation of microvascularization: acceleration of an autocrine sensing mechanism facilitating chemotaxis by inorganic polyph…

2018

The in vitro tube formation assay with human umbilical vein endothelial cells (HUVEC) was applied to identify the extra- and intracellular sources of metabolic energy/ATP required for cell migration during the initial stage of microvascularization. Extracellularly, the physiological energy-rich polymer, inorganic polyphosphate (polyP), applied as biomimetic amorphous calcium polyP microparticles (Ca-polyP-MP), is functioning as a substrate for ATP generation most likely via the combined action of the alkaline phosphatase (ALP) and the adenylate kinase (AK). The linear Ca-polyP-MP with a size of 40 phosphate units, close to the polyP in the acidocalcisomes in the blood platelets, were found …

0301 basic medicineOligomycinAdenylate kinaseNeovascularization PhysiologicBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAdenosine TriphosphateX-Ray DiffractionPolyphosphatesSpectroscopy Fourier Transform InfraredExtracellularHuman Umbilical Vein Endothelial CellsHumansGlycolysisMolecular BiologyTube formationATP synthasebiologyChemistryApyraseAdenylate Kinase (AK) ; Alkaline Phosphatase (ALP) ; ATP ; F0F1-ATP synthase ; inorganic polyphosphate ; microvascularization ; tube formation ; Human Umbilical Vein Endothelial Cells (HUVEC) ; nano/microparticles ; chemotaxis ; autocrine sensing.ChemotaxisCell BiologyCell biologyAutocrine Communication030104 developmental biology030220 oncology & carcinogenesisMicrovesselsbiology.proteinIntracellular
researchProduct

A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival

2016

AbstractMultiple myeloma (MM) is closely dependent on cross-talk between malignant plasma cells and cellular components of the inflammatory/immunosuppressive bone marrow milieu, which promotes disease progression, drug resistance, neo-angiogenesis, bone destruction and immune-impairment. We investigated the relevance of inflammatory genes in predicting disease evolution and patient survival. A bioinformatics study by Ingenuity Pathway Analysis on gene expression profiling dataset of monoclonal gammopathy of undetermined significance, smoldering and symptomatic-MM, identified inflammatory and cytokine/chemokine pathways as the most progressively affected during disease evolution. We then sel…

0301 basic medicineOncologyAdultMaleCandidate genemedicine.medical_specialtyBiologyIFNCCL503 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansMultiple myelomaAgedAged 80 and overInflammationHematologyComputational BiologyHematologyMiddle Agedmedicine.diseaseNeoplasm ProteinsGene expression profilingGene Expression Regulation Neoplasticmyeloma030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisImmunologygene expressionDisease ProgressionOriginal ArticleFemaleIL17ABone marrowMultiple MyelomaTranscriptomeMonoclonal gammopathy of undetermined significanceSignal TransductionBlood Cancer Journal
researchProduct

Time dependent expression of the blood biomarkers EIF2D and TOX in patients with schizophrenia

2019

Background During last years, there has been an intensive search for blood biomarkers in schizophrenia to assist in diagnosis, prognosis and clinical management of the disease. Methods In this study, we first conducted a weighted gene coexpression network analysis to address differentially expressed genes in peripheral blood from patients with chronic schizophrenia (n?=?30) and healthy controls (n?=?15). The discriminating performance of the candidate genes was further tested in an independent cohort of patients with first-episode schizophrenia (n?=?124) and healthy controls (n?=?54), and in postmortem brain samples (cingulate and prefrontal cortices) from patients with schizophrenia (n?=?3…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyCandidate geneTime FactorsImmunologyEukaryotic Initiation Factor-2Gene ExpressionPrefrontal CortexDiseaseCohort Studies03 medical and health sciencesBehavioral Neuroscience0302 clinical medicineImmune systemPrognosis of schizophreniaInternal medicinemedicineHumansGeneEndocrine and Autonomic Systemsbusiness.industryCase-control studyHigh Mobility Group ProteinsBrainMiddle Agedmedicine.diseasePrognosis030104 developmental biologySchizophreniaCase-Control StudiesCohortSchizophreniaFemalebusinessTranscriptome030217 neurology & neurosurgeryBiomarkers
researchProduct

miR-1226 detection in GCF as potential biomarker of chronic periodontitis: a pilot study

2018

Background The study and identification of new biomarkers for periodontal disease, such as microRNAs (miRNAs), may give us more information about the location and severity of the disease and will serve as a basis for treatment planning and disease-monitoring. miRNAs are a group of small RNAs which are involved in gene regulation by binding to their messenger RNA target (mRNA). In this pilot study, the procedure for purifying miRNAs from gingival crevicular fluid (GCF) was, for the first time, described. In addition, the concentration of miRNAs in GCF was analyzed and compared between patients with moderate or severe chronic periodontitis (CP) and healthy controls. Material and Methods GCF s…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyPilot ProjectsDisease03 medical and health sciencesInternal medicinemicroRNAmedicineHumansGeneral DentistryPeriodontitisRegulation of gene expressionMessenger RNAOral Medicine and Pathologybusiness.industryResearchGingival Crevicular FluidMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseChronic periodontitisReverse transcription polymerase chain reactionMicroRNAs030104 developmental biologyOtorhinolaryngologyChronic PeriodontitisUNESCO::CIENCIAS MÉDICASBiomarker (medicine)SurgeryFemalebusinessBiomarkers
researchProduct

Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.

2021

Primary triple-negative invasive lobular breast carcinomas (TN-ILCs), which do not express hormone receptors and HER2 at diagnosis, are rare and poorly known. In this study, we analyzed the largest TN-ILC series ever reported in the literature, in comparison to phenotypically similar breast tumor subtypes: triple-negative invasive ductal carcinoma (TN-IDC) and hormone receptor-positive invasive lobular carcinoma (HR + ILC). All primary TN-ILCs registered in our database between 2000 and 2018 (n = 38) were compared to tumors from control groups, matched by stage and Elston/Ellis grade, with regard to clinical, pathologic, and immunohistochemical characteristics. A comparative molecular analy…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPathologyReceptor ErbB-2Lobular carcinomaDNA Mutational AnalysisTriple Negative Breast NeoplasmsArticlePathology and Forensic Medicine03 medical and health sciencesBasal (phylogenetics)Phosphatidylinositol 3-Kinases0302 clinical medicineBreast cancerInternal medicinemedicineCarcinomaHumansskin and connective tissue diseasesSurvival analysisAgedAged 80 and overbusiness.industryMiddle Agedmedicine.diseaseAndrogen receptorbody regionsCarcinoma Lobular030104 developmental biologyPleomorphism (cytology)Receptors EstrogenReceptors Androgen030220 oncology & carcinogenesisInvasive lobular carcinomaMutationFemalebusinessModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
researchProduct

TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.

2018

Abstract Triple-negative breast cancer (TNBC) is an aggressive disease lacking targeted therapy. In this study, we developed a CAR T cell–based immunotherapeutic strategy to target TEM8, a marker initially defined on endothelial cells in colon tumors that was discovered recently to be upregulated in TNBC. CAR T cells were developed that upon specific recognition of TEM8 secreted immunostimulatory cytokines and killed tumor endothelial cells as well as TEM8-positive TNBC cells. Notably, the TEM8 CAR T cells targeted breast cancer stem–like cells, offsetting the formation of mammospheres relative to nontransduced T cells. Adoptive transfer of TEM8 CAR T cells induced regression of established…

0301 basic medicineOncologyCancer ResearchAdoptive cell transfermedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentT-LymphocytesCell- and Tissue-Based TherapyReceptors Antigen T-CellApoptosisReceptors Cell SurfaceTriple Negative Breast NeoplasmsTargeted therapy03 medical and health sciencesMice0302 clinical medicineBreast cancerAntigenInternal medicineBiomarkers TumorTumor Cells CulturedMedicineAnimalsHumansTriple-negative breast cancerCell Proliferationbusiness.industryMicrofilament ProteinsCancerImmunotherapyTriple Negative Breast Neoplasmsmedicine.diseasePrognosisXenograft Model Antitumor AssaysNeoplasm ProteinsSurvival Rate030104 developmental biologyOncology030220 oncology & carcinogenesisCase-Control StudiesFemaleImmunotherapybusinessFollow-Up StudiesCancer research
researchProduct

Transcriptomic and Genetic Associations between Alzheimer's Disease, Parkinson's Disease, and Cancer.

2021

Simple Summary Epidemiological studies have identified a link between neurodegenerative disorders and a reduced risk of overall cancer. Increases and decreases in the risk of site-specific cancers have also been reported. However, it is still unknown whether these associations arise due to shared genetic and molecular factors or are explained by other phenomena (e.g., biases in epidemiological studies or the use of medication). In this study, we aimed to investigate the potential molecular, genetic, and pharmacological links between Alzheimer’s and Parkinson’s diseases and a large panel of 22 cancer types. To examine the overlapping involvement of genes and pathways, we obtained differentia…

0301 basic medicineOncologyCancer ResearchParkinson's diseaseGenetic correlationsGenome-wide association studyDiseaseComorbidityParkinson Enfermedad de - Aspectos genéticos.chemistry.chemical_compound0302 clinical medicineExemestaneParkinson's disease - Genetic aspects.MedicineParkinsonCáncer - Aspectos genéticos.Càncer -- Aspectes genèticsRC254-282Alzheimer's disease - Genetic aspects.NeurodegenerationNeoplasms. Tumors. Oncology. Including cancer and carcinogensCódigo genético.comorbidityOncology:Informàtica::Aplicacions de la informàtica::Bioinformàtica [Àrees temàtiques de la UPC]medicine.medical_specialtyGenetic code.Alzheimer Enfermedad de - Aspectos genéticos.Article03 medical and health sciencesInternal medicineParkinson Malaltia dePI3K/AKT/mTOR pathwaygenetic correlationsCancer - Genetic aspects.business.industryCancertranscriptomicmedicine.diseaseComorbidityAlzheimer Malaltia d'030104 developmental biologychemistryTranscriptomicmeta-analysesMeta-analysesNeurodegenerative disordersAlzheimerGene expressionbusiness030217 neurology & neurosurgeryCancers
researchProduct

PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival.

2017

Background: PTTG1-interacting protein (PTTG1IP) is an oncogenic protein, which participates in metaphase-anaphase transition of the cell cycle through activation of securin (PTTG1). PTTG1IP promotes the shift of securin from the cell cytoplasm to the nucleus, allowing the interaction between separase and securin. PTTG1IP overexpression has been previously observed in malignant disease, e.g. in breast carcinoma. However, the prognostic value of PTTG1IP in breast carcinoma patients has not previously been revealed. Methods: A total of 497 breast carcinoma patients with up to 22-year follow-up were analysed for PTTG1IP and securin immunoexpression. The results were evaluated for correlations w…

0301 basic medicineOncologyCancer ResearchTriple Negative Breast NeoplasmsKaplan-Meier EstimatePBF0302 clinical medicineBreast cancerSurgical oncologyRisk FactorsAged 80 and overrintasyöpäPTTG1 interacting proteinIntracellular Signaling Peptides and ProteinsCell cycleMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisImmunohistochemistrySecurinsyöpägeenitOncologySecurin030220 oncology & carcinogenesisImmunohistochemistryFemaleSeparaseBreast carcinomaResearch ArticleAdultmedicine.medical_specialtyPTTG1IPBreast Neoplasmslcsh:RC254-282immunohistokemia03 medical and health sciencesBreast cancerInternal medicineGeneticsmedicineBiomarkers TumorHumansAgedbusiness.industryMembrane Proteinsmedicine.disease030104 developmental biologyMultivariate AnalysisCancer researchprognosisproteiinitbusinessBMC cancer
researchProduct

SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer

2020

New treatment strategies such as immune checkpoint inhibitors and oncolytic viruses are opening new possibilities in cancer therapy. Preliminary results in melanoma and other tumors showed that the combination of talimogene laherparepvec with an anti-PD-1/PD-L1 or anti-CTLA4 has greater efficacy than either therapy alone, without additional safety concerns beyond those expected for each agent. The presence of residual cancer after neoadjuvant chemotherapy in early breast cancer patients is an unmet medical need. SOLTI-1503 PROMETEO is a window of opportunity trial, which evaluates the combination of talimogene laherparepvec in combination with atezolizumab in women with operable HER2-negati…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBreast NeoplasmsHerpesvirus 1 HumanAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineBreast cancerClinical ProtocolsAtezolizumabInternal medicineClinical endpointHumansMedicineImmune Checkpoint InhibitorsTriple-negative breast cancerNeoplasm StagingOncolytic VirotherapyBiological ProductsClinical Trials as Topicbusiness.industryMelanomaGeneral MedicineImmune Checkpoint Proteinsmedicine.diseaseCombined Modality TherapyOncolytic virusClinical trial030104 developmental biologyOncologyResearch Design030220 oncology & carcinogenesisFemalebusinessTalimogene laherparepvecFuture Oncology
researchProduct

Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer

2021

BackgroundThe prognosis of early breast cancer is linked to clinic-pathological stage and the molecular characteristics of intrinsic tumor cells. In some patients, the amount and quality of tumor-infiltrating immune cells appear to affect long term outcome. We aimed to propose a new tool to estimate immune infiltrate, and link these factors to patient prognosis according to breast cancer molecular subtypes.MethodsWe performed in silico analyses in more than 2800 early breast cancer transcriptomes with corresponding clinical annotations. We first developed a new gene expression deconvolution algorithm that accurately estimates the quantity of immune cell populations (tumor immune contexture,…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMyeloid2435In silicoImmunologyCellbiostatisticsBreast NeoplasmsTranscriptome03 medical and health sciences0302 clinical medicineBreast cancerImmune systemLymphocytes Tumor-InfiltratingInternal medicinemedicineBiomarkers TumorImmunology and Allergytumor microenvironmentHumans1506Stage (cooking)RC254-282Neoplasm StagingPharmacologyClinical/Translational Cancer ImmunotherapyTumor microenvironmentbusiness.industryGene Expression ProfilingNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrognosisSurvival AnalysisGene Expression Regulation Neoplastic030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesistumor biomarkersMolecular MedicineFemalebusinessAlgorithmsUnsupervised Machine LearningJournal for Immunotherapy of Cancer
researchProduct